Men with genital ulcers that were culture positive for Haemophiluss ducreyi were treated with intramuscular ceftriaxone and randomized to three different dose regimens. All but 1 of 50 men treated with 1 g of intramuscular ceftriaxone were cured. Similarly, 0.5 and 0.25 g cured 43 of 44 men and 37 of 38 men, respectively. A single dose of 250 mg of intramuscular ceftriaxone is an effective treatment for chancroid.
Haemophilus ducreyi strains has led us' to search for alternate treatment regimens for chancroid (7) . A 10-day course of erythromycin and a 1-week course of amoxicillin in combination with clavulanic acid are each satisfactory treatments, with cure rates of over 95% (2, 10) . More recently, we have shown that a single dose of trimethoprimsulfametrole (11) or of rifampin in combination with trimethoprim (12) can cure most patients with chancroid in Kenya. However, additional effective single-dose treatment regimens are necessary due to the recent emergence of trimethoprim-resistant H. ducreyi strains in Thailand (13) .
Ceftriaxone is remarkably effective -against H. ducreyi in vitro, with MICs of 0.015 mg/liter or'less for all isolates tested. In the present study, we compared three different single-dose intramuscular ceftriaxone regimens for the treatment of men with genital ulcer disease due to H. ducreyi.
MATERIALS AND METHODS
Between April and December 1982, male patients presenting at the Nairobi Special Treatment Clinic with a clihical syndrome compatible with chancroid were enrolled in the study. Men were eligible if'they were older than 18 years, had had no antimicrobial therapy in the preceding week, were willing to return for follow-up, and were negative for Treponema pallidum on dark-field examination. The external genitalia were examined, and the number, size, and clinical characteristics of the ulcers were noted. Buboes, defined as tender inguinal or femoral lymph nodes enlarged to more than 1 cm, were examined for fluctuance, consistency, and size. Ulcers were cultured for H. ducreyi and herpes simplex virus by techniques described in an earlier publication (11) . All ulcers were cultured on two different media, which in combination have been shown to support the growth of H. ducreyi from samples of ulcers from over 80% of patients with clinical chancroid (8) . Agar dilution ceftriaxone and other cephalosporin MICs for H. ducreyi were determined as described previously (4) . One or more dark-field examinations were performed on samples of all ulcers. Serum was obtained for serologic tests for syphilis initially and at 10 and 28 days.
Patients who had positive cultures for H. ducreyi and no evidence of T. pallidum infection were assigned by a preconstructed random sequence to treatment with ceftriax-* Corresponding author.
one in a dose of 1.0, 0.5, or 0.25 g. The ceftriaxone was administered intramuscularly after dilution in 1% xylocaine. The evaluator' was unaware of the treatment regimen selected.
The men were requested to return for follow-up visits after 3, 7, 10, 14, and 28 days. At follow-up visits, they were asked about sexual contacts, symptoms, and adverse effects of therapy. Ulcers and buboes, if present, were reevaluated and cultured.
Clinical cure was defined as the point at which complete epithelialization of the ulcer occurred. Bacteriological cure was defined as eradication of H. ducreyi in all cultures obtained after treatment. Clinical failure was said to have occurred when the ulcer failed to improve by day 7 or progressed on any visit after day 7.
RESULTS
After giving verbal informed consent, 182 patients with clinical chancroid and ulcer cultures positive for H. ducreyi were entereqd into the study. Sixty-eight were treated with 1.0 g, 60 with 0.5 g, and 54 with 0.25 g of ceftriaxone. There were no significant differences in age, duration of disease, ulcer size, or ulcer number between groups.
The results of therapy are shown in Table 1 . Fifty patients, or'28% of the men entered into the study, failed to return for adequate follow-up to ensure complete resolution. One patient treated with 1 g, two treated with 0.5 g, and three treated with 0.25 g of ceftriaxone were cult'ure positive at the day 3 visit. However, only three of these six patients went on to become clinical failures, one in each group. The ulcers in the other three patients healed, and the ulcer cultures were negative when repeated at 1 week.
Two patients, each treated with the 1-g dose, had recurrence of the ulcer. One relapsed 2 weeks following complete healing. Another had recurrence following sexual reexposure, and the ulcer was presumably a reinfection. Overall, the initial cure rates in these three groups of men with chancroid were 98, 98, and 97% for the 1.0-, 0.5-, and 0.25-g ceftriaxone groups, respectively. The response of the ulcers to the three treatment regimens was identical. In each group, over 90% of the ulcers had resolved completely by day 14 . The median duration to complete healing varied from 8 to 10 days, and the rate of healing was primarily dependent on the original ulcer size.
One-third of the patients in each group had buboes. These responded equally well to each of the treatment regimens The intramuscular injections were well tolerated. No allergic reactions and no sterile abscesses were identified during follow-up.
The susceptibility of H. ducreyi to ceftriaxone and five other cephalosporins is shown in Table 2 . All isolates produced P-lactamase, and all were susceptible to 0.003 mg or less of ceftriaxone per liter. Ceftriaxone is the most active of all the cephalosporins investigated to date against H. ducreyi.
DISCUSSION
The pharmacokinetics of ceftriaxone, combined with its remarkable in vitro efficacy, have made it an excellent drug for the single-dose treatment of gonococcal urethritis and gonococcal ophthalmia neonatorum (3, 5) . A dose of 125 mg intramuscularly has been effective in gonococcal infections, effectively eradicating infection from all sites (5). The present study shows that ceftriaxone in a dose as low as 250 mg cures over 97% of patients with genital ulcer disease caused by H. ducreyi. Due to the efficacy of each of the three regimens, we failed to demonstrate any relationship between dose and response. Taylor et al. have reported an equally high cure rate in patients with chancroid in Thailand treated with 250 mg of ceftriaxone (14) . Earlier studies showed that the eradication of H. ducreyi and cure of chancroid required drug levels in blood above the MIC for H. ducreyi for between 36 and 48 h (1). An intramuscular dose of 250 mg of ceftriaxone provides antibacterial agent levels above the MIC for H. ducreyi for about 72 h (9). The persistence of H. ducreyi in ulcer cultures taken at 72 h for 3 of 145 patients who subsequently went on to resolution without additional treatment is unexplained. We have not observed this in earlier studies.
Will H. ducreyi acquire resistance to ceftriaxone? The use of subtherapeutic doses to treat sexually transmitted infections may permit the stepwise emergence of resistance or appearance of plasmids mediating a unique P-lactamase.
Continuing surveillance is required.
T. pallidum infection frequently occurs concomitantly with H. ducreyi. Ceftriaxone has been shown to be bactericidal for T. pallidum (6) , and the single-dose regimen prescribed for gonococcal infection may be effective for incubating syphilis infections. However, more prolonged treatment regimens are required to cure patients with T. pallidum infection (E. W. Hook III, R. E. Roddy, and H. H. Handsfield, Meet. 6th Int. Soc. Sex. Transm. Dis. Res., poster no. 172). All patients with genital ulcers should have one or preferably two dark-field examinations and serologic tests to exclude syphilis prior to the use of a therapeutic agent such as ceftriaxone, which may make the dark-field examination negative without eradicating T. pallidum from other sites.
Ceftriaxone has been demonstrated to be a remarkably effective agent for the single-dose treatment of sexually transmitted diseases due to Neisseria gonorrhoeae and H. ducreyi. Further studies are needed to determine its efficacy in patients with incubating or infectious syphilis. ACKNOWLEDGMENTS This study was supported by grants from Hoffmann-La Roche, Basel, Switzerland, and from the Medical Research Council of Canada (MA7495).
